[go: up one dir, main page]
More Web Proxy on the site http://driver.im/
Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Matters Arising
  • Published:

Fitness effects of CRISPR/Cas9-targeting of long noncoding RNA genes

Nature Biotechnology volume 38, pages 573–576 (2020)Cite this article

Subjects

Matters Arising to this article was published on 24 February 2020

The Original Article was published on 05 November 2018

Access through your institution
Buy or subscribe

arising from Liu et al. Nature Biotechnology https://doi.org/10.1038/nbt.4283 (2018)

Long noncoding RNAs (lncRNAs) are a large class of transcripts that do not encode proteins, and while some lncRNAs are known to have important functions in mammalian cells, the function of the large majority of lncRNAs remains to be explored in depth. Thus, large-scale and unbiased approaches to screen for functional lncRNA loci are critical for the advancement of this field. Moreover, as any single approach will likely be affected by both false positives and false negatives, there is clear value in having a multitude of orthogonal strategies for exploring lncRNA function. Liu et al.1 recently have presented an approach for systematically investigating lncRNA function by targeting the CRISPR/Cas9 nuclease to lncRNA splice acceptor/donor sites. Although the approach is clearly a valuable addition to the arsenal of strategies used to characterize lncRNA function, there are some important caveats as well. Specifically, the authors identified 469 lncRNA loci that confer fitness defects in three cell lines when their splice sites were targeted in this manner. To validate lncRNA hits and their overall approach, they used paired Cas9 targeting to remove lncRNA exons. We find evidence that a substantial fraction of the hits in these screens (at least 30–39% in each cell line) are likely to be false positives due to either nuclease activity in copy number-amplified regions or overlap with protein-coding genes. Furthermore, the validation method chosen by the authors was not sufficiently orthogonal to identify such false positives.

This is a preview of subscription content, access via your institution

Access options

Access through your institution

Buy this article

  • Purchase on SpringerLink
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: LncRNA CRISPR screen hits inside copy-number-amplified regions or overlapping protein-coding genes.
Fig. 2: Top lncRNA screen hits in HeLa cells are located in the HPV18 integration locus.

Data availability

All analysis was performed on previously published datasets. Sources and accession numbers are tabulated in the Supplementary Methods.

Code availability

All code used for analysis, figure generation and preparation for visualization in genome browsers is included as a Jupyter Notebook in Supplementary File 1. Software dependencies and versions are listed in the Supplementary Methods.

References

  1. Liu, Y. et al. Genome-wide screening for functional long noncoding RNAs in human cells by Cas9 targeting of splice sites. Nat. Biotechnol. 36, 1203–1210 (2018).

    Article  CAS  Google Scholar 

  2. Wu, S. Q. et al. Extensive amplification of BCR/ABL fusion genes clustered on three marker chromosomes in human leukemic cell line K-562. Leukemia 9, 858–862 (1995).

    CAS  PubMed  Google Scholar 

  3. Wang, T. et al. Identification and characterization of essential genes in the human genome. Science 350, 1096–1101 (2015).

    Article  CAS  Google Scholar 

  4. Horlbeck, M. A. et al. Compact and highly active next-generation libraries for CRISPR-mediated gene repression and activation. eLife 5, e19760 (2016).

    Article  Google Scholar 

  5. Liu, S. J. et al. CRISPRi-based genome-scale identification of functional long noncoding RNA loci in human cells. Science 355, aah7111 (2017).

    Article  Google Scholar 

  6. Bassett, A. R. et al. Considerations when investigating lncRNA function in vivo. eLife 3, e03058 (2014).

    Article  Google Scholar 

  7. Xiang, J.-F. et al. Human colorectal cancer-specific CCAT1-L lncRNA regulates long-range chromatin interactions at the MYC locus. Cell Res. 24, 513–531 (2014).

    Article  CAS  Google Scholar 

  8. Adey, A. et al. The haplotype-resolved genome and epigenome of the aneuploid HeLa cancer cell line. Nature 500, 207–211 (2013).

    Article  CAS  Google Scholar 

  9. Jia, L., Zhang, Y., Tian, F., Chu, Z. & Xin, H. Long noncoding RNA colon cancer associated transcript-1 promotes the proliferation, migration and invasion of cervical cancer. Mol. Med. Rep. 16, 5587–5591 (2017).

    Article  CAS  Google Scholar 

  10. Wu, L. et al. Full-length single-cell RNA-seq applied to a viral human cancer: applications to HPV expression and splicing analysis in HeLa S3 cells. Gigascience 4, 51 (2015).

    Article  Google Scholar 

  11. Aguirre, A. J. et al. Genomic copy number dictates a gene-independent cell response to CRISPR/Cas9 targeting. Cancer Discov. 6, 914–929 (2016).

    Article  CAS  Google Scholar 

  12. Munoz, D. M. et al. CRISPR screens provide a comprehensive assessment of cancer vulnerabilities but generate false-positive hits for highly amplified genomic regions. Cancer Discov. 6, 900–913 (2016).

    Article  CAS  Google Scholar 

  13. Meyers, R. M. et al. Computational correction of copy number effect improves specificity of CRISPR-Cas9 essentiality screens in cancer cells. Nat. Genet. 49, 1779–1784 (2017).

    Article  CAS  Google Scholar 

  14. Gonçalves, E. et al. Structural rearrangements generate cell-specific, gene-independent CRISPR-Cas9 loss of fitness effects. Genome Biol. 20, 27 (2019).

    Article  Google Scholar 

  15. Morgens, D. W. et al. Genome-scale measurement of off-target activity using Cas9 toxicity in high-throughput screens. Nat. Commun. 8, 15178 (2017).

    Article  CAS  Google Scholar 

  16. Cho, S. W. et al. Promoter of lncRNA Gene PVT1 Is a tumor-suppressor DNA boundary element. Cell 173, 1398–1412.e22 (2018).

    Article  CAS  Google Scholar 

Download references

Acknowledgements

The authors were supported by the University of California San Francisco Medical Scientist Training Program (M.A.H. and S.J.L.); NIH grant nos. F30NS092319-01 (S.J.L.), 1R01NS0091544 (D.A.L.) and R35CA209919 (H.Y.C.) and the Howard Hughes Medical Institute (M.A.H., H.Y.C. and J.S.W.).

Author information

Author notes

  1. Max A. Horlbeck

    Present address: Boston Children’s Hospital, Boston, MA, USA

Authors and Affiliations

  1. Department of Cellular & Molecular Pharmacology, University of California, San Francisco, San Francisco, CA, USA

    Max A. Horlbeck & Jonathan S. Weissman

  2. Howard Hughes Medical Institute, University of California, San Francisco, San Francisco, CA, USA

    Max A. Horlbeck & Jonathan S. Weissman

  3. California Institute for Quantitative Biomedical Research, University of California, San Francisco, San Francisco, CA, USA

    Max A. Horlbeck & Jonathan S. Weissman

  4. Department of Neurological Surgery, University of California, San Francisco, CA, USA

    S. John Liu & Daniel A. Lim

  5. Eli and Edythe Broad Center of Regeneration Medicine and Stem Cell Research, University of California, San Francisco, CA, USA

    S. John Liu & Daniel A. Lim

  6. Center for Personal Dynamic Regulomes, Stanford University, Stanford, CA, USA

    Howard Y. Chang

  7. Department of Dermatology, Stanford University, Stanford, CA, USA

    Howard Y. Chang

  8. Department of Genetics, Stanford University, Stanford, CA, USA

    Howard Y. Chang

  9. Howard Hughes Medical Institute, Stanford University, Stanford, CA, USA

    Howard Y. Chang

  10. San Francisco Veterans Affairs Medical Center, San Francisco, CA, USA

    Daniel A. Lim

Authors
  1. Max A. Horlbeck
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. S. John Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Howard Y. Chang
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Daniel A. Lim
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Jonathan S. Weissman
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

M.A.H. performed the analysis. S.J.L. contributed to CCAT1 analysis. M.A.H., S.J.L., H.Y.C., D.A.L. and J.S.W. wrote the manuscript and provided critical feedback.

Corresponding author

Correspondence to Jonathan S. Weissman.

Ethics declarations

Competing interests

M.A.H. and J.S.W. have filed a patent application related to CRISPR interference screening (15/326,428).

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

Supplementary Methods and Figs. 1 and 2.

Method description and two figures

Reporting Summary

Supplementary File 1

Jupyter notebook containing all analysis scripts. Notebook is provided in HTML and Jupyter notebook (.ipynb) formats.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Horlbeck, M.A., Liu, S.J., Chang, H.Y. et al. Fitness effects of CRISPR/Cas9-targeting of long noncoding RNA genes. Nat Biotechnol 38, 573–576 (2020). https://doi.org/10.1038/s41587-020-0428-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41587-020-0428-0

This article is cited by

Search

Advanced search

Quick links

Nature Briefing: Translational Research

Sign up for the Nature Briefing: Translational Research newsletter — top stories in biotechnology, drug discovery and pharma.

Get what matters in translational research, free to your inbox weekly. Sign up for Nature Briefing: Translational Research